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Recent improvements in the understanding of glioblastoma (GBM) have allowed for increased ability to develop specific, targeted
therapies. In parallel, however, there is a need for effective methods of delivery to circumvent the therapeutic obstacles presented
by the blood-brain barrier and systemic side effects. The ideal delivery system should allow for adequate targeting of the tumor
while minimizing systemic exposure, applicability across a wide range of potential therapies, and have existing safe and efficacious
systems that allow for widespread application. Though many alternatives to systemic delivery have been developed, this paper will
focus on our experience with convection-enhanced delivery (CED) and our focus on translating this technology from pre-clinical
studies to the treatment of human GBM.
1. Introduction
Malignant gliomas are among the most pernicious of human
tumors and are characterized as regionally invasive, usu-
ally recurring within two centimeters of their origin after
resection [1]. Although many advances in treatment have
been made, they have yielded only modest survival benefits
[2]. Numerous chemotherapeutic drugs have demonstrated
significant antitumor activity in preclinical studies, but often
this effectiveness is not translated into clinical trials in
humans. A major factor contributing to this is the limitation
of systemic delivery, namely, the impermeability of the blood-
brain barrier as well as dose-limiting toxicities of many
compounds. This highlights the need for efficient, specific
methods of delivery in the treatment of human GBM.
The ideal delivery method would be one that achieves
adequate coverage of the tumor volume while minimizing
any unwanted toxicities. Optimal delivery requires three
important components: the ability to target the tumor while
minimizing local and systemic effects, applicability over
a wide range of therapies, and a safe, efficacious method of
continuous delivery with noninvasive methods to monitor
volumes of distribution (Vd) of agents. In this paper, we
describe our experience with convection-enhanced delivery
(CED) across these three domains and highlight the transla-
tional goals of this work. The ultimate goal is to safely bring
such systems and therapies to human trials, and eventually,
to optimize these methods in clinical practice and establish
standards of care.
2. Convection-Enhanced Delivery
Convection-enhanced delivery, pioneered by Bobo et al.,
delivers agents directly into the tumor and the surrounding
parenchyma with continuous, positive-pressure infusion [3].
While other methods of delivery exist, such as through
intraarterial and intrathecal routes, these are often limited by
the blood-brain and blood-CSF barrier as well as unwanted
toxicities. Furthermore, compared to diffusion-based drug
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Figure 1: (a) The local delivery of PBS for 7 days into PDGF-
expression retrovirus-induced tumor (large arrow—injection site)
demonstrates a large proliferative lesion with notable pseudopal-
isading necrosis (small arrows) and invasion across the corpus
callosum (CC). (b) The delivery of topotecan for 7 days results in
significant decrease in tumor cells. (Figure reprinted with permis-
sion from Lopez et al. [5].)
delivery (i.e., carmustine wafers), convective delivery allows
for larger volumes of distribution, as it is not limited by diffu-
sive spread by concentration gradients [4]. Importantly, CED
allows direct access to the tumor bed, achieving high local
concentrations of drug with minimal systemic absorption.
One of the first therapeutic agents given via CED for
malignant gliomas in a clinical trial was diphtheria toxin
conjugated to transferrin (TF-CRM107) [9]. This pioneering
clinical trial highlighted the capability of CED to maximize
therapeutic effect while limiting toxicity, as adverse events
were limited. Several Phase I and II studies with other
targeted cytotoxins followed in succeeding years, including
IL-4, IL-13, transforming growth factor (TGF)-a conjugated
to pseudomonas exotoxin, herpes simplex virus (HSV)-
1-tk gene-containing liposomes, and 131I-labeled chimeric
monoclonal antibody to histone H1 (Cotara) [10–14]. These
trials demonstrated tumor specificity and adequate agent
distribution with adverse effects similarly limited to target
tissue damage and minimal to no systemic toxicity. These
trials were limited, however, by the specificity of the delivered
agents, which targeted only a subpopulation of tumor cells.
Prior to our clinical trial, paclitaxel was the only conventional
chemotherapeutic agent delivered via CED in a clinical trial
[15]. This was mainly because paclitaxel does not cross the
BBB, thus allowing the investigators to demonstrate that DW-






























Figure 2: The local delivery of topotecan by convection-enhanced
delivery resulted in significant survival advantage when compared
to PBS treated controls. This effect was greater with longer periods
of therapy. (Figure reprinted with permission from Lopez et al. [5].)
of CED. The trial resulted in a large incidence (40%) of
chemical meningitis, a major drawback to the choice of
paclitaxel [15, 16]. Though these studies highlighted initial
challenges in the application of CED, they demonstrated the
importance of careful and rational selection of agents for use
in this method of delivery.
3. Early Experiences: CED of Topotecan
Our initial experience with CED of antitumor agents utilized
the cytotoxic agent topotecan. Topotecan is a camptothecin-
class drug and acts as a topoisomerase-I inhibitor. It causes
single-strand DNA breaks during DNA replication [17, 18].
This drug was selected after we demonstrated in vitro cyto-
toxicity against various malignant glioma cell lines [19]. Due
to its activity in cells in the S-phase of division, topotecan is
ideal for the treatment of mitotically active glioma cells in the
setting of relatively quiescent brain tissue. Previous experi-
ence with topotecan demonstrated poor penetration of the
blood-brain barrier and significant dose-limiting toxicities,
limiting systemic administration [20–23]. However, these
same properties make it an ideal drug for administration via
CED.
In addition, an important aspect of the choice of topote-
can was its effect on a vital cellular process, namely, the
role of topoisomerase I on DNA processes. This focus on
conventional chemotherapeutic agents as opposed to targeted
therapies allows for greater coverage of heterogeneous glioma
subpopulations. While targeted therapies can be successful
in eliminating a specific subpopulation of glioma cells that
express a certain antigen, this provides a selective advantage
for remaining neoplastic cells.
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Figure 3: (a) 4 patients of the 16 treated demonstrated an immediate decrease in contrast enhancing volume following CED of topotecan,
classified as early responders. (b) Serial T1 weighted, contrast MRI sequences from a selected patient demonstrating significant response with
complete resolution at 1.5 years. Recurrence was noted at 2.5 years posttreatment. (Figure reprinted with permission from Bruce et al. [6].)
Preclinical testing of topotecan that was performed in
a model of glioblastoma was developed using a PDGF-
B expressing retrovirus injected stereotactically into the
adult white matter of rats to infect glial progenitors [19].
This resulted in the consistent development of tumors
that closely resembled glioblastoma, with pseudopalisading
necrosis, invasion, glomeruloid vascular proliferation, and
survival of 14–19 days [24]. Topotecan was delivered using
an implantable osmotic pump connected to an intracerebral
infusion cannula (Alzet; Cupertino, CA) that was implanted
into the tumor. A significant survival advantage was demon-
strated in glioma-bearing rats treated with topotecan at
concentrations significantly less than those used in systemic
studies. Further, we found that animals treated for a longer
period of time demonstrated increased survival benefit (1 d
versus 4 d versus 7 d) [5] (Figure 1). Importantly, no adverse
effects of the medication were observed.
Given the promising results of our preclinical studies, a
Phase I, dose escalation clinical trial was undertaken to treat
patients with recurrent glioblastoma with CED of topotecan.
Topotecan was delivered to 18 patients with radiographically
and pathologically confirmed recurrent high-grade glioma.
While not primarily designed to test treatment efficacy, this
clinical trial demonstrated that theCEDof topotecan resulted
in radiographic tumor regression in 69% of patients, with
25%demonstrating an early response, at a drug concentration
nontoxic to normal brain with minimal drug-associated
systemic toxicity [6] (Figure 2). This demonstrated that CED
is an effective method of bypassing the blood-brain barrier to
achieve targeted antitumor effect withminimal dose-limiting
toxicities. Furthermore, topotecan proved to be a potent
antitumor drug when delivered appropriately and directly to
the tumor.
4. CED as a Platform to Assess Novel
Antitumor Agents
Various classes of drugs have been proposed as potential
antitumor agents. CED is a valuable platform to assess
the feasibility of administering these agents in vivo. For
example, virus-mediated gene therapy has proven to be a
promising modality to allow for tumor-specific delivery of
gene constructs. However, the initial experience with these
agents has been hindered by poor distribution [25]. We have
found that CED is a viable method of distributing adenovi-
ral particles widely across white matter tracts in a rodent
model (Figure 3(a)). Furthermore, with the modification of
these particles with supraparamagnetic iron oxide particles
(Figure 5), we were able to characterize MRI signatures that
would allow of the real-time monitoring of vector distribu-
tion (Figure 3(b)) [7].
CED allows for direct assessment of newly selected drugs
by maximizing the specific delivery to the tumor, especially
as the molecular understanding of human GBM continues
to identify new potential targets. Based on the work of
Verhaak et al., GBM has been subdivided based on 4 dis-
tinct molecular signatures: classical, neural, proneural, and




Figure 4: Infusion of an adenoviral vector (Ad5) expressing GFP and rhodamine-dextran demonstrates distribution of the vector throughout
the ipsilateral white matter at (a) rostral and (b) caudal sections of the brain. (Figure reprinted with permission from Yun et al. [7].)
mesenchymal [26]. Our group has developed a mouse model
of glioma which is induced by injecting a retrovirus that
expresses PDGF-B and cre recombinase into the subcortical
white matter of transgenic mice that harbor floxed alleles
of the tumor suppressor genes, PTEN and p53. We found
that the expression profile of these tumors closely resembles
the proneural subtype of GBM [27]. This model provides
a powerful tool to assess therapies in treating this specific
subtype of GBM. Also, by understanding the molecular
profile of this subtype, rational selection of antitumor agents
can be pursued.
Within human TCGA data, we found that topoiso-
merases are differentially expressed across the 4GBM sub-
types, with proneural subtype showing the highest levels of
both TOP2a and TOP2b expressions.The elevated expression
of topoisomerase II seen in the proneural subgroup suggested
that these tumors might be particularly sensitive to inhibitors
of topoisomerase II. We also found elevated expression of
topoisomerase II compared to topoisomerase I in ourmurine
model of proneural GBM (Carminucci et al. [28]).
Based on these findings, we hypothesized that etoposide,
a topoisomerase II inhibitor, would exhibit effective cytotox-
icity against the proneural subtype of GBM.We are currently
undergoing preclinical testing with local, continuous delivery
of etoposide in our mouse model of proneural GBM, which
demonstrates significant antitumor activity and prolonged
survival (Carminucci et al. [28]). We hope to translate these
findings into early Phase I and II trials and to assess clinical
and radiographic response with an understanding of the
specific molecular subtypes of tumors treated.
5. Prolonged CED with Implantable
Subcutaneous Pumps
In our initial clinical trial, we demonstrated the ability of CED
to deliver and effectively treat tumors with chemotherapy,
all while bypassing the blood brain barrier and minimizing
systemic toxicity. These clinical studies utilized externalized
catheters, which, due to an increasing risk of infection with
longer placement, shortened the treatment period to 4 days
[6]. As mentioned above, in our rodent model, we demon-
strated that prolonged delivery of topotecan is associatedwith
increased survival. Therefore, we sought to develop a system
for prolonged delivery that could be safely applied in the
clinical setting.
To this end, we have employed an implantable subcuta-
neous pump (Synchromed II, Medtronic; Minneapolis, MN),
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Figure 5: (a) Local injection of a superparamagnetic iron oxide nanoparticle labeled adenovirus demonstrates a T2-intense, GRE positive
signal at the site of injection when compared to the contralateral, saline-injected side. (b) Volume analysis demonstrates a greater T2-intense
volume with adenovirus injection when compared to saline. (Figure reprinted with permission from Yun et al. [7].)
already FDA approved for the treatment of spasticity and
chronic pain. To assess this system in the pre-clinical setting,
the pig model was used due to the larger size of the brain in
comparison to the rodent model and its similarity to human
gray/white matter composition. The pump was implanted
into a subcutaneous pocket in the pig’s back, and silastic
catheter was tunneled subcutaneously and inserted into the
frontal whitematter.The reservoir was filledwith amixture of
topotecan and/or gadolinium and was infused over a period
of 10 days. The volumes of distribution were followed with
serial MRI, and safety and toxicity were assessed on a daily
basis [8].
In this study, we demonstrated safety of topotecan with
prolonged intracerebral infusion in nontumor bearing ani-
mals. Furthermore, topotecan retained its antitumor bioac-
tivity after prolonged exposure to physiologic conditions.
We demonstrated stability of the volume of distribution of
gadolinium with prolonged delivery, with rapid reabsorption
of contrast following cessation of infusion [8] (Figure 4).
Along with the tolerability of the implanted pump, these
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Figure 6: Prolonged infusion (10 d) with an implanted subcuta-
neous pump results in stable volumes of distribution.Themaximum
relative volume was reached 2-3 days after infusion was initiated.
With infusion discontinued at day 3, enhancing volume is seen to
dissipate. (Figure reprinted with permission from Sonabend et al.
[8].)
findings provide justification for translation of this system
to clinical trials, and we hope to employ this system for the
treatment of human gliomas.
6. Challenges
The administration of therapeutics via CED is not without
its challenges, most notably the leakage of refluxed infusate
along the catheter [29]. Other risks include infection, as well
as those related to the drug, including potential systemic
events if the agent is able to cross the blood-brain barrier.
In our experience, however, the biologically active doses of
the therapeutic agent administered via CED are well below
systemic dose limiting toxicities. As Saito et al. have demon-
strated, the volume of distribution (Vd) (Figure 6) achieved
by CED is dependent on multiple compound specific factors
(i.e., lipophilicity), as well as anatomical variables (i.e., tumor
architecture and white matter tracks) [30]. The potential
volumes achievable with CED, however, are greater than the
volumes achieved by implantable wafers and diffusion-based
therapies [31].
7. Discussion
Convection-enhanced delivery provides a method of local
delivery of antitumor agents directly to the tumor and the
surrounding infiltrative edges. Benefits of this system include
volumes of distribution not limited by the physical charac-
teristics of the drug or diffusive spread along concentration
gradients [4]. This allows for the administration of a wide
range of antitumor drugs that have been previously limited
by systemic toxicities and poor distribution.
Further, this method of delivery allows for greater flex-
ibility with drug development and selection, as the effects
of the blood brain barrier and systemic metabolism are
minimized with direct, targeted delivery to the tumor. With
the development of an implantable system that allows for
prolonged delivery, it is conceivable that GBM can be treated
chronically with single or multiple, sequential agents. Thus,
our experience with CED demonstrates the ability to target
tumors for the local delivery of a wide range of therapies,
with systems that allow for a safe transition to the treatment
of patients.
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